Astellas Pharma (Astellas Pharma) FCF Margin % : 8.57% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Astellas Pharma's Free Cash Flow for the three months ended in Dec. 2023 was $251 Mil. Astellas Pharma's Revenue for the three months ended in Dec. 2023 was $2,930 Mil. Therefore, Astellas Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 8.57%.

As of today, Astellas Pharma's current FCF Yield % is 5.31%.

The historical rank and industry rank for Astellas Pharma's FCF Margin % or its related term are showing as below:

ALPMY' s FCF Margin % Range Over the Past 10 Years
Min: 8.42 Med: 14.25 Max: 20.94
Current: 8.42

During the past 13 years, the highest FCF Margin % of Astellas Pharma was 20.94%. The lowest was 8.42%. And the median was 14.25%.

ALPMY's FCF Margin % is ranked better than
73.17% of 1025 companies
in the Drug Manufacturers industry
Industry Median: -0.67 vs ALPMY: 8.42

Astellas Pharma FCF Margin % Historical Data

The historical data trend for Astellas Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma FCF Margin % Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

15.81

11.08

18.36

13.96

15.75

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															12.83	24.69	-1.11	1.52	8.57

Competitive Comparison of Astellas Pharma's FCF Margin %

For the Drug Manufacturers - General subindustry, Astellas Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's FCF Margin % falls into.

Astellas Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Astellas Pharma's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	1789.753	/	11361.441
	=	15.75 %

Astellas Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	251.033	/	2930.46
	=	8.57 %

Astellas Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.